News

Exelixis Advances Cabozantinib for Neuroendocrine Tumors

Exelixis Advances Cabozantinib for Neuroendocrine Tumors

Exelixis Regulatory Update on Cabozantinib (CABOMETYX)

Exelixis, Inc. (Nasdaq: EXEL) announced an important update regarding its supplemental New Drug Application (sNDA) for cabozantinib, branded as CABOMETYX. This application, aimed at treating adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic neuroendocrine tumors (epNET), will be reviewed by the U.S. Food and Drug Administration (FDA). The FDA has scheduled a discussion of the sNDA during an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025.

Details of the CABINET Trial

The basis of this sNDA stems from promising results delivered by the phase 3 CABINET pivotal trial, which was rigorously conducted by the National Cancer Institute's National Clinical Trials Network. This trial evaluated cabozantinib against a placebo in patients suffering from advanced forms of pNET and epNET. Notably, within the context of the trial's results, Exelixis received orphan drug designation from the FDA for cabozantinib treatments.

Significant Milestones for Exelixis

Earlier in the year, Exelixis proudly announced that the FDA recognized cabozantinib’s potential by granting it orphan drug status for treating pNET. The Prescription Drug User Fee Act has assigned an action target date of April 3, 2025, further emphasizing the regulatory body's recognition of the drug's therapeutic promise.

Cabozantinib's Pivotal Trials and Recommendations

The CABINET trial concluded with the Alliance for Clinical Trials in Oncology independent Data and Safety Monitoring Board recommending the immediate cessation of enrollment and the unblinding of randomized patients to receive cabozantinib as there was a significant improvement in progression-free survival (PFS) observed during interim analysis. Final results, shared at the 2024 European Society of Medical Oncology Congress, indicated that cabozantinib produced statistically significant improvements in PFS when compared to placebo.

Understanding Neuroendocrine Tumors

Neuroendocrine tumors (NET) arise from specialized cells within the body’s neuroendocrine system. These tumors often start in locations such as the gastrointestinal tract and lungs, with the pancreas being a site known for more aggressive forms of these tumors. Statistics indicate that the prevalence of NET is on the rise in the United States, and it’s estimated that between 161,000 and 192,000 individuals are living with unresectable or metastatic NET.

Current Treatment Options and CABOMETYX

For patients with advanced NET, treatment advancements are critical. Existing options may involve somatostatin analogs, chemotherapy, targeted therapies, and peptide–receptor radionuclide therapy. While cabozantinib is a cornerstone of Exelixis’ portfolio, it is essential to note that CABOMETYX remains unapproved for NET but plays a significant role in other cancer treatments, including advanced renal cell carcinoma and hepatocellular carcinoma.

Potential Risks and Safety Considerations

As with any medication, safety considerations are paramount. Cabozantinib may lead to severe hemorrhage, including fatal outcomes in some cases. Additionally, patients undergoing treatment may experience gastrointestinal issues, hypertension, and hepatotoxicity. It’s essential for healthcare providers to monitor these conditions closely and provide necessary interventions when required.

Exelixis' Commitment to Innovation

Exelixis continues its commitment to pioneering cancer treatment through innovative research and drug development. With a focus on expanding its product offerings for different tumor types, Exelixis remains dedicated to developing groundbreaking therapies aimed at enhancing patient outcomes. As advancements in medicine continue, the importance of ongoing clinical trials and regulatory discussions cannot be overstated.

Frequently Asked Questions

What is the significance of the FDA's discussion on the sNDA for cabozantinib?

The FDA's review of the sNDA indicates important regulatory momentum, reflecting the drug's potential therapeutic benefits for patients with previously treated advanced neuroendocrine tumors.

What were the outcomes of the CABINET trial?

The CABINET trial showed statistically significant improvements in progression-free survival in patients treated with cabozantinib compared to those receiving placebo.

What types of tumors does cabozantinib aim to treat?

Cabozantinib is aimed primarily at treating advanced renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer.

What safety concerns are associated with cabozantinib?

Safety concerns for cabozantinib include severe hemorrhages, hypertension, and gastrointestinal issues, among others, which require careful monitoring during treatment.

How does Exelixis contribute to cancer research?

Exelixis is heavily invested in cancer research, focusing on developing innovative therapies and clinical trials to enhance treatment options and outcomes for cancer patients.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Sokin’s UAE License Turns Expansion Into Real Payments Plumbing

Updated Category News Views 97

Dubai expansion headlines are cheap; regulated local money movement is not. That is why Sokin’s newly approved Dubai Financial Services Authority license deserves more than the usual fintech applause line. The company has paired that approval with AED accounts, local payment rails, a One Za’abeel office and a plan to double its UAE staff over the next year. None of...

Continue Reading
Marelli’s Two Awards Put Practical Auto Tech in Focus

Updated Category News Views 43

Two trophies in Novi do not fill an order book, but Marelli’s latest pair says something useful about where automotive suppliers are trying to earn their keep. The company collected a 2026 Automotive News PACE Award for HorizonView and a PACE Pilot Award for Affordable 5G RedCap at the November 17 ceremony. One is already deployed in production; the other is a...

Continue Reading
LONGi's Solar-Storage Push Faces Africa's Cost Wall

Updated Category News Views 75

A vaccine refrigerator humming through a blackout is more meaningful than another climate-conference slogan. That was the useful thread running through LONGi's November 13 COP31 side event in Antalya, Türkiye: solar and storage are not merely hardware for remote communities. When designed, financed and maintained properly, they can keep clinics, water pumps and other...

Continue Reading
Sysco's Northern California Labor Deal Gets Bigger

Updated Category News Views 0

One hundred forty-four drivers may not rattle a giant food distributor by themselves, but labor agreements have a habit of growing legs. Sysco's Northern California and Nevada regional contract has added members from Teamsters Locals 386 and 431, bringing its coverage above 1,100 workers. For investors watching Sysco, this is less about one afternoon's headline and more...

Continue Reading
Sunbit’s 2027 Loan Push Meets an NVIDIA-Fueled Tape

Updated Category News Views 116

Credit Is About to Enter Sunbit’s Growth Story Sunbit has spent years building a point-of-sale fintech footprint, and the numbers it cited on November 18 make the next step harder to dismiss as mere marketing fluff. The company says it has topped 400,000 activated cardholders and 50,000 merchants, while expecting more than $440 million in fiscal 2026 sales on greater...

Continue Reading
Precision Metal Forming Is Industry's Quiet Backbone

Updated Category News Views 72

A fraction of a millimeter can turn a perfectly good industrial part into an expensive headache. That unglamorous reality sits at the center of Michele Caulfield's discussion of precision metal forming for HelloNation, and it deserves more attention than it usually gets. Investors watching manufacturing tend to chase flashy automation headlines, big aerospace orders, or...

Continue Reading
Envision and Tai Tam Put 45 MW Wind Bet to Work in Vietnam

Updated Category News Views 177

A wind site averaging 6.5 meters per second can look unremarkable on a map, yet that is precisely where equipment choices start separating serious developers from brochure merchants. Envision Energy and Vietnam's Tai Tam Group are taking that test on with the 45 MW Phuoc Dan wind project in Khanh Hoa Province. The arrangement follows five years of cooperation, but the...

Continue Reading
Three Cash Buyouts Draw Fresh Shareholder Scrutiny

Updated Category News Views 149

Three cash-price tags landed on the tape with a lawyerly asterisk attached: are public holders actually getting a fair shake? On November 18, 2026, Halper Sadeh LLC said it was investigating proposed sales involving Surgery Partners, Braze and CCC Intelligent Solutions. That is not a finding of misconduct, and investors ought to keep that distinction bolted firmly to the...

Continue Reading
Marina del Rey's Travel Award Brings Fresh Attention

Updated Category News Views 39

A harbor town just got handed a useful little megaphone. On November 18, 2026, the Marina del Rey Tourism Board said Marina del Rey had been selected as a winner in Good Housekeeping's 2027 Travel Awards. That is not a quarterly earnings event, and nobody ought to dress it up as one. Still, in the visitor economy, recognition from a broad consumer publication can matter...

Continue Reading
Berlin Heals Puts Microcurrent Therapy to a Real Test

Updated Category News Views 34

A silent electrical signal is heading into the sort of trial that separates intriguing ideas from credible medical evidence. Berlin Heals Holding AG has initiated C-MIC IV, an international randomized, double-blind, sham-controlled study of its implanted microcurrent therapy for symptomatic heart failure. The first patient has already been implanted in Kragujevac, Serbia....

Continue Reading

Top 5 Most Recently Viewed Articles

SAIHEAT Unveils Innovations at SC24 for Sustainable Data Centers

Updated Category News Views 237

SAIHEAT Showcases Groundbreaking Solutions at SC24 SAIHEAT Limited (formerly SAI.TECH Global Corporation) (NASDAQ: SAIH, SAITW) is excited to announce its inaugural appearance at the Supercomputing 2024 (SC24) Conference. This pivotal event takes place from November 18-21 in Atlanta, providing SAIHEAT a platform to present innovative technologies designed for the future...

Continue Reading
NetEase: A Comprehensive SWOT Analysis Amidst Market Changes

Updated Category News Views 879

NetEase (NASDAQ: NTES), Inc. faced significant hurdles back in 2024 as it battled through a maturing gaming landscape. Known for its dominance in China's online gaming sector, the company encountered delays in game releases that shook investor confidence and triggered a reevaluation of future projections by analysts. While its mobile offerings continued to pull weight,...

Continue Reading
MIMARU Eases Travel in Tokyo with New Support Hub

Updated Category News Views 44

Tourists and Tokyo: MIMARU Bridges the Gap Imagine you're trekking through the bustling streets of Tokyo with your family, and out of nowhere, the heavens open and send down a torrent. Your phone’s dead, you’re drenched to the bone, and the kids are whining in sync about needing to find a restroom. Now, wouldn't it be nice to have a friendly place nearby offering a...

Continue Reading
Exploring the Rapid Growth of the Cloud Logistics Sector

Updated Category News Views 248

Understanding the Cloud Logistics Landscape The Cloud Logistics Market is on an impressive growth trajectory, projected to reach a staggering USD 76.42 billion by the end of the forecast period. This remarkable estimation follows a significant rise from its previous valuation of USD 27.69 billion in 2024, indicating a compound annual growth rate (CAGR) of 13.53% from 2025...

Continue Reading
Institute of Culinary Education Honors 2025 Graduates at Ceremony

Updated Category News Views 615

Institute of Culinary Education Celebrates Its Graduates The Institute of Culinary Education (ICE) is set to honor its latest culinary graduates with an inspiring commencement ceremony at its Los Angeles campus. As ICE marks this important milestone in its history, it is also a moment to celebrate the institution's 50th anniversary, where culinary dreams turn into...

Continue Reading